Phase 1b Study to Investigate the Safety and Immunogenicity of Cam2020 (A/Cambodia/e0826360/2020) M2SR H3N2 Monovalent Influenza Vaccine Administered Alone or With Licensed, Inactivated Influenza Vaccine in Adults 65 to 85 Years Old
Latest Information Update: 22 Jul 2024
At a glance
- Drugs H3N2 M2SR influenza vaccine-FluGen (Primary) ; Influenza virus vaccine (Primary)
- Indications Influenza A virus H3N2 subtype
- Focus Adverse reactions
- Sponsors FluGen
- 12 Jul 2024 According to a FluGen media release, data from this study were published in the journal Lancet Infectious Diseases.
- 11 Nov 2022 Status changed from active, no longer recruiting to completed.
- 06 Oct 2022 Status changed from recruiting to active, no longer recruiting.